Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans […]